Ian Somaiya is a Managing Director and Senior Research Analyst at Piper Jaffray & Co. covering the biotechnology industry. Prior to joining Piper Jaffray in 2010, Mr. Somaiya worked in equity research at Thomas Weisel Partners Group. Mr. Somaiya was recognized as Best on the Street by The Wall Street Journal in 2006, 2007 and 2009 for his biotechnology coverage. Formerly, Mr. Somaiya was a Senior Analyst at Morgan Stanley with responsibilities for small- and mid-capitalization biotechnology companies. He spent a year with The Carson Group in its health care consulting practice prior to making his transition to the sell-side at Prudential Securities. Mr. Somaiya received a B.A. in biology/neuroscience from New York University.
